You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨貝康醫療、錦欣生殖大升6%,上海將12項輔助生殖技術納入醫保支付
港股市場輔助生殖概念股走強,其中,貝康醫療升近6%,錦欣生殖升超7%。消息面上,6月1日起上海將12項輔助生殖技術納入醫保支付。為實施積極生育支持措施,近日上海市醫保局會同人力資源社會保障、衞生健康部門印發《關於將部分治療性輔助生殖技術項目納入醫保、工傷保險支付範圍的通知》,上海將把12項輔助生殖類醫療服務項目納入醫保支付範圍,涵蓋取卵術、取精術、人工授精、胚胎培養、胚胎移植等必要醫療性輔助生殖技術,自2024年6月1日起執行,預計每年可為參保人員減輕負擔約9億元。據不完全統計,截至目前,北京、廣西、內蒙古、甘肅、江西、上海已先後將輔助生殖納入醫保報銷。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account